Results 111 to 120 of about 3,692,049 (193)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

open access: yesCancer Management and Research, 2019
Tristan Knight,1,2 Holly Edwards,3,4 Jeffrey W Taub,1–2,4 Yubin Ge2–41Division of Pediatric Hematology and Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, MI, USA; 2Department of Pediatrics, Wayne State ...
Knight T, Edwards H, Taub JW, Ge Y
doaj  

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

open access: yesMedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng   +9 more
wiley   +1 more source

Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas

open access: yesNature Communications
Single-cell transcriptome profiling enables unparalleled characterization of the heterogeneous microenvironment of pediatric leukemias. To facilitate comparative analyses and generate pediatric leukemia signatures, we collect, process, and annotate ...
Hope L. Mumme   +12 more
doaj   +1 more source

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities

open access: yesMedComm, Volume 7, Issue 9, September 2026.
Major types of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming involved in autoimmune diseases. The roles of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming in autoimmune diseases have been a major research focus in recent years.
Jialong Kuang   +10 more
wiley   +1 more source

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 9, September 2026.
Protein posttranslational modifications, including phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, glycosylation, and other new types, dynamically regulate antigen presentation and recognition, immune signal transduction, antibody production and class switching, immune contraction, immune memory establishment, as well as immune ...
Yuxing Yao   +10 more
wiley   +1 more source

Oxidative and Antioxidant Systems in Ferroptosis of Cancer: Mechanisms, Regulations, and Therapeutic Targeting

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
Ferroptosis is governed by the balance between reactive oxygen species (ROS)‐driven lipid peroxidation and a multi‐tiered antioxidant network. ROS sources include mitochondrial electron transport chain, voltage‐dependent anion channels, NADPH oxidases, and endoplasmic reticulum‐resident oxidoreductases, while antioxidant defenses span the primary GSH ...
Deepak K   +5 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

Cloning of a Carcinoembryonic Antigen Gene Family Member Expressed in Leukocytes of Chronic Myeloid Leukemia Patients and Bone Marrow [PDF]

open access: yes, 1990
The carcinoembryonic antigen (CEA) gene family belongs to the immunoglobulin superfamily and can be subdivided into the CEA and pregnancy-specific glycoprotein subgroups.
Kolbinger, Frank   +7 more
core   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

open access: yesMedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Home - About - Disclaimer - Privacy